|
|
|
 |
FDA Approval Activities for this Drug…
Ellence (epirubicin hydrochloride) Injection, 50 mg/25 mL & 200 mg/100 mL single-use vials, Pharmacia & Upjohn NDA 50-778/S3 & S4 4/3/03 4/18/03 Ellence (epirubicin hydrochloride), 50 mg/25 mL & 200 mg/100 mL single-use vials; Intravenous, Pharmacia & Upjohn NDA 50-778 9/15/99 9/24/99 9/24/99 1/30/03 Ellence Indication: Indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. | Ellence (epirubicin hydrochloride) injection, Pfizer, Efficacy Supplement w/Clinical Data to Support | Epirubicin Hydrochloride Injection, Mayne Pharma, Tentative Approval | Epirubicin Hydrochloride for Injection lyophilized, Mayne Pharma, Approval | Epirubicin Hydrochloride Injection, Mayne Pharma, Approval | Epirubicin Hydrochloride Injection, Bedford Labs, Approval | Epirubicin Hydrochloride Injection, Teva Parenteral, Approval | Epirubicin Hydrochloride Injection, Dabur Oncology, Approval | Epirubicin Hydrochloride Injection, Abraxis Pharma, ApprovalEpirubicin Hydrochloride Injection, Watson Labs, Approval | Epirubicin Hydrochloride Injection, GeneraMedix Inc., Approval | Epirubicin Hydrochloride Injection, Activis Totowa, LLC, Approval | Epirubicin Hydrochloride Injection, Akorn Inc., Approval | Epirubicin Hydrochloride Injection, EBEWE Pharma, Approval | Epirubicin Hydrochloride Injection, X-GEN Pharmaceuticals, Inc., Approval | Epirubicin Hydrochloride Injection, Sagent Pharmaceuticals, Inc., Approval | Ellence (epirubicin hydrochloride) Injection, Pfizer, Inc., Labeling Revision
  
|